Sandoz DO Brasil IND Farmaceutica Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: Sandoz DO Brasil IND Farmaceutica Pharmaceutical Import Records from India — 2 Products, $2.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sandoz DO Brasil IND Farmaceutica — Pharmaceutical Importer Profile (2026) | 2 Products, $2.0M Trade | TransData Nexus

Sandoz DO Brasil IND Farmaceutica

Pharmaceutical Importer · Brazil · CNS & Psychiatric Focus · $2.0M Total Trade · DGFT Verified

Sandoz DO Brasil IND Farmaceutica is a pharmaceutical importer based in Brazil with a total trade value of $2.0M across 2 products in 1 therapeutic categories. Based on 40 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sandoz DO Brasil IND Farmaceutica sources from 1 verified Indian supplier, with Sandoz Private Limited accounting for 100.0% of imports.

Sandoz DO Brasil IND Farmaceutica — Import Portfolio & Supplier Network

Sandoz DO Brasil IND Farmaceutica import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sandoz DO Brasil IND Farmaceutica?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sandoz Private Limited	$3.8M	142	100.0%

Sandoz DO Brasil IND Farmaceutica sources from 1 verified Indian supplier across 88 distinct formulations. The sourcing is highly concentrated — Sandoz Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Apixabana 5MG 60fct br material no. -	$248.3K	7
Mirtazapine 15MG 7odt pp br material no.	$194.7K	6
Apixabana 2.5MG 60fct br material no.	$168.2K	6
Razapina 15MG 7odt pp br material no.	$129.2K	3
Material no-42030715, escitalopram oxa	$100.0K	2
Material no - 42030715, escitalopram	$100.0K	2
Material no 42030721 escitalopram oxafct 10MG in91 sh ms batch no mv2415 mv2420 mv2417 mfg date 15 02 2023	$100.0K	2
Fosfato de sitagliptina 100MG 30fct br material no. -	$100.0K	2
Fosfato de sitagliptina 100MG 60fct br material no. -	$95.8K	2
Material no.-42031184, escitalopram	$92.1K	2
Fosfato de sitagliptina 50MG 30fct br material no. -	$86.7K	2
Mirtazapine nov 15MG 7odt pp br materialno. -	$83.0K	4
Mirtazapine nov 15MG 7odt pp br	$79.6K	5
Mirtazapine 15MG 7odt pp br material no.-	$60.7K	2
Material no. 43000499 topiramato sdz 100MG 10fct pp	$57.1K	2

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Citalopram	CNS & Psychiatric	$1.0M	20	0.4%	20
2	Escitalopram	CNS & Psychiatric	$1.0M	20	0.5%	14

Sandoz DO Brasil IND Farmaceutica imports 2 pharmaceutical products across 1 categories into Brazil totaling $2.0M.

Sandoz DO Brasil IND Farmaceutica — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sandoz do Brasil Indústria Farmacêutica Ltda., headquartered in Cambé, Paraná, Brazil, is a subsidiary of Sandoz AG, a global leader in generic pharmaceuticals and biosimilars. Established on July 19, 1966, the company specializes in the manufacturing and distribution of generic medications, focusing on providing affordable and high-quality alternatives to branded drugs. Sandoz do Brasil plays a pivotal role in Brazil's pharmaceutical distribution network, ensuring the availability of essential medications across the country. (aboutcompany.info)

2Distribution Network

Sandoz do Brasil operates a robust distribution network with facilities strategically located to serve the Brazilian market effectively. The company's primary manufacturing plant is situated in Cambé, Paraná, which serves as a central hub for production and distribution. Additionally, Sandoz do Brasil maintains a distribution center in Embu das Artes, São Paulo, enhancing its logistical capabilities and ensuring timely delivery of products nationwide. (cnpj.biz)

3Industry Role

Within Brazil's pharmaceutical supply chain, Sandoz do Brasil functions as a primary wholesaler and distributor. The company imports finished pharmaceutical formulations from various global suppliers, including India, and distributes these products to pharmacies, hospitals, and healthcare providers across Brazil. By offering a diverse portfolio of generic medications, Sandoz do Brasil contributes significantly to increasing access to essential drugs and supports the sustainability of the Brazilian healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sandoz DO Brasil IND Farmaceutica

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sandoz do Brasil's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. This focused approach allows the company to leverage India's competitive pricing and established manufacturing standards. However, the reliance on a single supplier introduces potential risks, such as supply chain disruptions or geopolitical factors affecting trade relations. The stability of this sourcing relationship is crucial for maintaining uninterrupted product availability in the Brazilian market.

2Supply Chain Resilience

The resilience of Sandoz do Brasil's supply chain is closely tied to its partnership with Indian suppliers. While the company imports a diverse range of finished pharmaceutical formulations, the heavy reliance on a single supplier may pose challenges in the event of production issues or regulatory changes in India. To mitigate these risks, Sandoz do Brasil could consider diversifying its supplier base and establishing contingency plans to ensure a continuous supply of essential medications.

3Strategic Implications

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the Agência Nacional de Vigilância Sanitária (ANVISA) is the primary regulatory authority overseeing the pharmaceutical sector. ANVISA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products through rigorous regulatory processes. Key legislation governing pharmaceutical imports includes Law No. 9,782/1999, which established ANVISA, and subsequent resolutions that outline the requirements for market authorization, importation, and distribution of pharmaceutical products. (gov.br)

2Import Licensing & GMP

Import licensing in Brazil requires that pharmaceutical products, including finished formulations, obtain pre-market approval from ANVISA before being marketed. This process involves submitting comprehensive documentation demonstrating compliance with Brazilian health regulations. Additionally, ANVISA recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are essential for ensuring the quality and safety of imported pharmaceutical products. (gov.br)

3Quality & Labeling

Sandoz DO Brasil IND Farmaceutica — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sandoz do Brasil's focus on importing pharmaceutical formulations in the Central Nervous System (CNS) and Psychiatric therapeutic category aligns with the growing demand for mental health treatments in Brazil. Medications such as Citalopram and Escitalopram are widely prescribed for depression and anxiety disorders, reflecting the company's strategic emphasis on addressing prevalent health concerns. This product strategy positions Sandoz do Brasil to meet the needs of a significant patient population seeking effective mental health therapies.

2Sourcing Profile

Sandoz do Brasil's sourcing strategy centers on importing generic drug formulations from India, leveraging the country's established pharmaceutical manufacturing capabilities and cost advantages. The company's preference for finished formulations over active pharmaceutical ingredients (APIs) indicates a focus on ready-to-market products that can be swiftly distributed within Brazil. This approach streamlines the supply chain and ensures a consistent supply of essential medications to the Brazilian market.

3Market Positioning

By importing and distributing generic pharmaceutical formulations, Sandoz do Brasil serves multiple segments of the Brazilian market, including retail pharmacies, hospitals, and government tenders. The company's product mix, particularly in the CNS and Psychiatric category, positions it to cater to the needs of patients requiring mental health treatments, thereby contributing to the overall healthcare infrastructure in Brazil.

Seller's Guide — How to Become a Supplier to Sandoz DO Brasil IND Farmaceutica

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Sandoz do Brasil, especially in therapeutic areas where there is a high demand for generic medications. Identifying gaps in Sandoz do Brasil's current sourcing, such as unmet needs in specific therapeutic categories or formulations, could present avenues for new suppliers to enter the Brazilian market. Establishing partnerships with Sandoz do Brasil could facilitate access to a broad distribution network and a significant customer base.

2Requirements & Qualifications

Indian exporters aiming to supply Sandoz do Brasil must ensure that their products comply with ANVISA's regulatory requirements, including obtaining the necessary pre-market approvals and adhering to GMP standards recognized by ANVISA. Products must undergo batch testing and stability studies to meet Brazilian health standards. Additionally, labeling must be in Portuguese, providing comprehensive product information as mandated by ANVISA. (gov.br)

3How to Approach

Frequently Asked Questions — Sandoz DO Brasil IND Farmaceutica

What products does Sandoz DO Brasil IND Farmaceutica import from India?

Sandoz DO Brasil IND Farmaceutica imports 2 pharmaceutical products across 1 categories. Top imports: Citalopram ($1.0M), Escitalopram ($1.0M).

Who supplies pharmaceuticals to Sandoz DO Brasil IND Farmaceutica from India?

Sandoz DO Brasil IND Farmaceutica sources from 1 verified Indian suppliers. The primary supplier is Sandoz Private Limited (100.0% of imports, $3.8M).

What is Sandoz DO Brasil IND Farmaceutica's total pharmaceutical import value?

Sandoz DO Brasil IND Farmaceutica's total pharmaceutical import value from India is $2.0M, based on 40 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sandoz DO Brasil IND Farmaceutica focus on?

Sandoz DO Brasil IND Farmaceutica imports across 1 categories. The largest: CNS & Psychiatric (100.0%).

Get Full Sandoz DO Brasil IND Farmaceutica Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.